Novo Nordisk’s Investigational Oral Semaglutide Shows Promising Weight Loss Results in Phase 1b/2a Trial
Oral semaglutide shows promising weight loss results in a Phase 1b/2a trial. Participants achieved significant weight reduction across various doses compared to placebo, offering a potential new non-injectable option.